Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses
Roche announced positive topline results of the phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral, showing a reduction in the transmission of influenza viruses. The study met its primary endpoint, demonstrating that a single, oral …